Multiple Myeloma

Multiple myeloma is a cancer that begins in plasma cells, a type of white blood cell. These cells are part of your immune system, which helps protect the body from germs and other harmful substances. In time, myeloma cells collect in the bone marrow and in the solid parts of bone.
What is Multiple Myeloma?

Multiple myeloma is a form of cancer that affects the bone marrow. The cancer is also called Kahler’s disease, named after an Austrian pathologist called Otto Kahler who first described the condition.

Read More

Overview

Feature Articles

Latest Multiple Myeloma News and Research

CAR T-cell therapy produces deep, sustained remissions in patients with relapsed myeloma

CAR T-cell therapy produces deep, sustained remissions in patients with relapsed myeloma

Benjamin L. Ebert receives Sjöberg Prize for breakthrough research on blood cancer

Benjamin L. Ebert receives Sjöberg Prize for breakthrough research on blood cancer

Immunomodulatory drugs improve the success rate of cancer therapies

Immunomodulatory drugs improve the success rate of cancer therapies

Study reveals mechanisms behind sensitivity of multiple myeloma cells to EZH2 inhibition

Study reveals mechanisms behind sensitivity of multiple myeloma cells to EZH2 inhibition

Study provides new insights into the mechanism of bone marrow tissue

Study provides new insights into the mechanism of bone marrow tissue

DSMB recommends continuation of Phase 2/3 study of opaganib for severe COVID-19

DSMB recommends continuation of Phase 2/3 study of opaganib for severe COVID-19

Two enzymes fuel transition from pre-cancer stem cells to leukemia stem cells

Two enzymes fuel transition from pre-cancer stem cells to leukemia stem cells

Designer DNA agent reduces myeloma stem cell abundance, lowers disease burden in mice

Designer DNA agent reduces myeloma stem cell abundance, lowers disease burden in mice

Seniors face crushing drug costs as Congress stalls on capping Medicare out-of-pockets

Seniors face crushing drug costs as Congress stalls on capping Medicare out-of-pockets

P2 COVID-19 study shows no material safety differences between opaganib and control arms

P2 COVID-19 study shows no material safety differences between opaganib and control arms

Phase 2/3 COVID-19 study evaluates safety, potential identification of preliminary efficacy signals

Phase 2/3 COVID-19 study evaluates safety, potential identification of preliminary efficacy signals

Landmark study finds how often cancer patients develop osteonecrosis of the jaw

Landmark study finds how often cancer patients develop osteonecrosis of the jaw

Ohio State receives $10 million gift to establish new myeloma research center

Ohio State receives $10 million gift to establish new myeloma research center

RedHill Biopharma announces promising preliminary results from opaganib study

RedHill Biopharma announces promising preliminary results from opaganib study

Study highlights previously unknown mechanisms involved in myeloma resistance

Study highlights previously unknown mechanisms involved in myeloma resistance

Clinical investigators present abstracts on hematological malignancies at ASH Annual Meeting and Exposition

Clinical investigators present abstracts on hematological malignancies at ASH Annual Meeting and Exposition

More than 40 Dana-Farber studies to be presented at the virtual 62nd ASH Annual Meeting

More than 40 Dana-Farber studies to be presented at the virtual 62nd ASH Annual Meeting

Underrepresented minorities are at increased risk for AL amyloidosis

Underrepresented minorities are at increased risk for AL amyloidosis

Beat AML trial achieves primary endpoint

Beat AML trial achieves primary endpoint

Advancements in research on cancer signal transduction and treatment

Advancements in research on cancer signal transduction and treatment